Literature DB >> 15821756

Annexin-1 peptide Anx-1(2-26) protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia.

Rebecca H Ritchie1, Jennifer M Gordon, Owen L Woodman, Anh H Cao, Gregory J Dusting.   

Abstract

1 The anti-inflammatory properties of annexin-1 peptides have been largely ascribed to their powerful antineutrophil actions in vivo. We have recently reported that the N-terminal fragment of annexin-1, Anx-1(2-26), preserves contractile function of cardiac muscle in vitro. The aim of the present study was to determine if Anx-1(2-26) elicits protective actions specifically on the cardiac myocyte (in the absence of neutrophils), using a model of metabolic inhibition to simulate ischaemia. 2 Metabolic inhibition of cardiac myocytes (4 h incubation at 37 degrees C in HEPES-containing buffer supplemented with 2-deoxy-D-glucose, D,L-lactic acid and pH adjusted to 6.5) followed by 2.5 h recovery in normal medium markedly increased creatine kinase (CK) and lactate dehydrogenase (LDH) levels by 179+/-39 and 26+/-7 IU L(-1) (both n=40, P<0.001), respectively. However, cellular injury was significantly decreased when Anx-1(2-26) (0.3 microM) was present during metabolic inhibition, CK by 74+/-10% and LDH by 71+/-6% (both n=31, P<0.001), respectively. 3 Boc 2 (10 microM), a nonselective formyl peptide receptor antagonist, present during metabolic inhibition, abolished the cardioprotective effect of Anx-1(2-26). 4 Addition of chelerythrine (10 microM), 5-hydroxydecanoate (500 microM) or SB202190 (1 microM) during metabolic inhibition also abolished Anx-1(2-26)-induced cardioprotection. 5 Cellular injury induced by metabolic inhibition was also largely prevented when myocytes were incubated with Anx-1(2-26) for 5 min with 10 min recovery prior to the insult, or when Anx-1(2-26) was present only during the recovery period following drug-free metabolic inhibition. 6 In conclusion, the annexin-1 peptide Anx-1(2-26) potently prevents cardiac myocyte injury induced by metabolic inhibition, an action that was dependent at least in part on the activation of the formyl peptide receptor family of G-protein-coupled receptors, protein kinase C, p38 mitogen-activated protein kinase and ATP-sensitive potassium channels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821756      PMCID: PMC1576163          DOI: 10.1038/sj.bjp.0706211

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Delayed preconditioning of cultured adult rat cardiac myocytes: role of 70- and 90-kDa heat stress proteins.

Authors:  M A Nayeem; M L Hess; Y Z Qian; K E Loesser; R C Kukreja
Journal:  Am J Physiol       Date:  1997-08

2.  Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment.

Authors:  M D'Amico; C Di Filippo; M La; E Solito; P G McLean; R J Flower; S M Oliani; M Perretti
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

Review 3.  The role of neutrophils in myocardial ischemia-reperfusion injury.

Authors:  J E Jordan; Z Q Zhao; J Vinten-Johansen
Journal:  Cardiovasc Res       Date:  1999-09       Impact factor: 10.787

4.  Lipocortin-1 preserves myocardial responsiveness to beta-adrenergic stimulation in rat papillary muscle.

Authors:  R H Ritchie; X Sun; G J Dusting
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-07       Impact factor: 2.557

5.  Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct.

Authors:  Felicity N E Gavins; Ahmad M Kamal; Michele D'Amico; Sonia M Oliani; Mauro Perretti
Journal:  FASEB J       Date:  2004-10-26       Impact factor: 5.191

6.  The annexin protein lipocortin 1 regulates the MAPK/ERK pathway.

Authors:  L C Alldridge; H J Harris; R Plevin; R Hannon; C E Bryant
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

7.  Antiinflammatory effect of lipocortin 1 in experimental arthritis.

Authors:  Y Yang; M Leech; P Hutchinson; S R Holdsworth; E F Morand
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

8.  Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study.

Authors:  R Dreier; K W Schmid; V Gerke; K Riehemann
Journal:  Histochem Cell Biol       Date:  1998-08       Impact factor: 4.304

9.  Priming effect of adenosine on K(ATP) currents in intact ventricular myocytes: implications for preconditioning.

Authors:  Y Liu; W D Gao; B O'Rourke; E Marban
Journal:  Am J Physiol       Date:  1997-10

10.  Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.

Authors:  N Chiang; I M Fierro; K Gronert; C N Serhan
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  20 in total

Review 1.  Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.

Authors:  Mauro Perretti; Jesmond Dalli
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

2.  Annexin-A1 deficiency exacerbates pathological remodelling of the mesenteric vasculature in insulin-resistant, but not insulin-deficient, mice.

Authors:  Maria Jelinic; Nicola Kahlberg; Chen Huei Leo; Hooi Hooi Ng; Sarah Rosli; Minh Deo; Mandy Li; Siobhan Finlayson; Jesse Walsh; Laura J Parry; Rebecca H Ritchie; Cheng Xue Qin
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

3.  Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.

Authors:  Fadi W Adel; Aruna Rikhi; Siu-Hin Wan; Seethalakshmi R Iyer; Hrishikesh Chakraborty; Steven McNulty; W H Wilson Tang; G Michael Felker; Michael M Givertz; Horng H Chen
Journal:  J Card Fail       Date:  2020-05-27       Impact factor: 5.712

Review 4.  The advantageous role of annexin A1 in cardiovascular disease.

Authors:  Renske de Jong; Giovanna Leoni; Maik Drechsler; Oliver Soehnlein
Journal:  Cell Adh Migr       Date:  2016-11-18       Impact factor: 3.405

5.  Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis.

Authors:  Thomas Gobbetti; Sina M Coldewey; Jianmin Chen; Simon McArthur; Pauline le Faouder; Nicolas Cenac; Roderick J Flower; Christoph Thiemermann; Mauro Perretti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

6.  Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26).

Authors:  Chengxue Qin; Keith D Buxton; Salvatore Pepe; Anh H Cao; Kylie Venardos; Jane E Love; David M Kaye; Yuan H Yang; Eric F Morand; Rebecca H Ritchie
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  Regulation of vascular endothelial growth factor-induced endothelial cell migration by LIM kinase 1-mediated phosphorylation of annexin 1.

Authors:  Maxime C Côté; Jessie R Lavoie; François Houle; Andrée Poirier; Simon Rousseau; Jacques Huot
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

8.  A fragmented form of annexin A1 is secreted from C2C12 myotubes by electric pulse-induced contraction.

Authors:  Naoko Goto-Inoue; Kotaro Tamura; Fumika Motai; Miyuki Ito; Kaede Miyata; Yasuko Manabe; Nobuharu L Fujii
Journal:  Mol Cell Biochem       Date:  2015-10-12       Impact factor: 3.396

9.  Ac2-26 mitigated acute respiratory distress syndrome rats via formyl peptide receptor pathway.

Authors:  Yingnan Ju; Lin Qiu; Xikun Sun; Hengyu Liu; Wei Gao
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

10.  Annexin peptide Ac2-26 suppresses TNFα-induced inflammatory responses via inhibition of Rac1-dependent NADPH oxidase in human endothelial cells.

Authors:  Hitesh M Peshavariya; Caroline J Taylor; Celeste Goh; Guei-Sheung Liu; Fan Jiang; Elsa C Chan; Gregory J Dusting
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.